Fuhong Hanlin (02696.HK): The National Medical Products Administration has approved the listing registration application of Hanshuang (Sulilumab injection) combined with chemotherapy for the new adjuvant/adjunct treatment indication of gastric cancer.

The Smart Financial APP reported that Fuhong Hanlin (02696.HK) announced that the National Medical Products Administration (NMPA) has recently approved the company's independently developed innovative anti-PD-1 monoclonal antibody Hanstang (Seerli monoclonal antibody injection) (Hanstang) in combination with oxaliplatin and tegafur for the neoadjuvant and postoperative adjuvant treatment of gastric cancer with tumor PD-L1 expression CPS5. New indications for registration application (NDA) on the market.